Table 1 Characteristics of included studies
Clinical trials | Age(years) | Gender (M/F) | Location | No. of patients gabapentin/control | Dose of gabapentin | Time of gabapentin administration |
|---|---|---|---|---|---|---|
Clarke 2009 Pre | 60.1 | 50/29 | Canada | 40/39 | 600 mg preoperatively | 2 h preoperatively |
Clarke 2009 Post | 60.9 | 43/34 | Canada | 38/39 | 600 mg postoperatively | In the recovery room |
Clarke 2010 Pre | 60.4 | 45/28 | Canada | 38/38 | 600 mg preoperatively | 2 h preoperatively |
Clarke 2010 Post | 61.7 | 44/35 | Canada | 38/38 | 600 mg postoperatively | In postanesthetic care unit |
Clarke 2010 | 60.8 | 43/27 | Canada | 22/48 | 600 mg | 2 h preoperatively |
Nantha 2011 | 61.1 | 52/41 | Canada | 45/48 | 800 mg on day 0, and 200 mg tid for 2 days | 2 h preoperatively and postoperatively |
Paul 2015 | 60.7 | 58/44 | Canada | 48/54 | 600 mg | 2 h preoperatively |